Moderate to Severe Psoriasis — Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
Citation(s)
A Single Arm, Open Label Study to Explore if Response to Intralesional Alefacept Injections Prior to the Standard Course of Intramuscular Treatment Can Predict Clinical Outcomes in Patients With Moderate to Severe Chronic Plaque Psoriasis